Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OR2 regimen (orelabrutinib + rituximab + lenalidomide) in untreated marginal zone lymphoma
ChiCTR2500115204Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, rituximab and lenalidomide in marginal zone B-cell lymphoma (MZL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
orelabrutinibrituximablenalidomide
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2500115204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115204.